My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format

Send to:

Choose Destination

    Asian J Androl. 2004 Dec;6(4):383-4.

    Anemia in patients on combined androgen block therapy for prostate cancer.

    Qian LX, Hua LX, Wu HF, Sui YG, Cheng SG, Zhang W, Li J, Wang XR.

    Department of Urology, First Affiliated Hospital, Nanjing Medical University, 210029,China. qianlx@jlonline.com.

    AIM: To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer. METHODS: One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy. RESULTS: The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05). CONCLUSION: Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.

    PMID: 15546035 [PubMed - indexed for MEDLINE]

    Publication Types, MeSH Terms, Substances

    Publication Types:

    MeSH Terms:

    Substances:

    LinkOut - more resources

    Medical:

    Libraries:

    Supplemental Content

    Related articles

    Patient drug information

    • Flutamide

      Flutamide is used together with a luteinizing hormone-releasing hormone agonist (LHRH; a type of hormonal injection such as leuprolide [Lupron, Eligard], goserelin [Zoladex], or triptorelin [Trelstar]) to treat certain t...

    • Source: AHFS Consumer Medication Information

    All links from this record

    • Related Articles

      Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.

    • Compound (MeSH Keyword)

      PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    • Substance (MeSH Keyword)

      PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

    Recent activity